Killip classification in patients with acute coronary syndrome: Insight from a multicenter registry

American Journal of Emergency Medicine

Volumn 30, Issue 1, 2012, Pages 97-103

  El Menyar, Ayman ^a   Zubaid, Mohammad ^b   Almahmeed, Wael ^c   Sulaiman, Kadhim ^d   Alnabti, Abdulrahman ^a   Singh, Rajvir ^e   Suwaidi, Jassim Al ^a  

^a HAMAD GENERAL HOSPITAL   (Qatar)

^b KUWAIT UNIVERSITY   (Kuwait)

^c SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^d ROYAL HOSPITAL   (Oman)

^e HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; DISEASE CLASSIFICATION; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; HEART INFARCTION; HOSPITAL PATIENT; HUMAN; KILLIP CLASSIFICATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACUTE CORONARY SYNDROME; ADRENERGIC BETA-ANTAGONISTS; AGED; ANGINA PECTORIS; DECISION SUPPORT TECHNIQUES; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITAL MORTALITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LENGTH OF STAY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; REGISTRIES; RISK FACTORS;

EID: 81755187756     PISSN: 07356757     EISSN: 15328171     Source Type: Journal    
DOI: 10.1016/j.ajem.2010.10.011     Document Type: Article

References (16)

1. Neskovic A.N., Otasevic P., Bojic M., and Popović A.D. Association of Killip class on admission and left ventricular dilatation after myocardial infarction: a closer look into an old clinical classification Am Heart J 137 1999 361 367
2. DeGeare V.S., Boura J.A., and Grines L.L. Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction Am J Cardiol 87 2001 1035 1038
3. Khot U.N., Jia G., and Moliterno D.J. Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification JAMA 290 2003 2174 2181
4. Zubaid M., Rashed W.A., and Almahmeed W. Management and outcomes of Middle Eastern patients admitted with acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE) Acta Cardiol 64 2009 439 446
5. El-Menyar A., Zubaid M., and Rashed W. Comparison of men and women with acute coronary syndrome in six Middle Eastern countries Am J Cardiol 104 2009 1018 1022
6. Alsheikh-Ali A.A., Al-Mallah M.H., and Al-Mahmeed W. Gulf RACE investigators. Heart failure in patients hospitalized with acute coronary syndromes: observations from the Gulf Registry of Acute Coronary Events (Gulf RACE) Eur J Heart Fail 11 2009 1135 1142
7. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes N Engl J Med 335 1996 775 782
8. The PURSUIT Trial Investigators Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes: platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy N Engl J Med 339 1998 436 443
9. The PARAGON Investigators International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina: platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a global organization network Circulation 97 1998 2386 2395
10. The PARAGON B Investigators Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes Circulation 105 2002 316 321
11. Emery M., López-Sendón J., and Steg P.G. Patterns of use and potential impact of early beta-blocker therapy in non-ST-elevation myocardial infarction with and without heart failure: the Global Registry of Acute Coronary Events Am Heart J 152 2006 1015 1021
12. Lopez de Sa E., Lopez-Sendon J., and Anguera I. Prognostic value of clinical variables at presentation in patients with non-ST-segment elevation acute coronary syndromes: results of the Proyecto de Estudio del Pronostico de la Angina (PEPA) Medicine (Baltimore) 81 2002 434 442
13. Nicod P., Gilpin E., and Dittrich H. Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after acute myocardial infarction Am J Cardiol 61 1988 1165 1171
14. Lee K.L., Woodlief L.H., Topol E.J. for the GUSTO-I Investigators Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients Circulation 91 1995 1659 1668
15. Launbjerg J., Berning J., and Fruergaard P. Risk stratification after acute myocardial infarction by means of echocardiographic wall motion scoring and Killip classification Cardiology 80 1992 375 381
16. Al-Reesi A., Al-Zadjali N., and Perry J. Do β-blockers reduce short-term mortality following acute myocardial infarction? a systematic review and meta-analysis CJEM 10 2008 215 223